Company Analysis
Sign in

Harmony Biosciences Holdings, Inc. (HRMY)

Nasdaq: HRMY · Pharmaceutical Preparations · Plymouth Meeting, PA · filing with the SEC since 2020
Full chart Alerts Compare
Grade7.0
◀ Past 8.4● Present 6.9▶ Future 5.6
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

4 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Harmony Biosciences Holdings, Inc.’s names, not what it holds today.

Patents granted
4
4 utility, 1976 to Dec 31, 2025
Granted in 2025
4
in the last year the record reads
Applications published
12
10 of them in 2025
Names they are printed under
3
a subsidiary
By yearGrantedApplications published
'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals4
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Harmony Biosciences Management, Inc. a subsidiary
US, as the owner printed on each patent
4 granted
9 published
HARMONY BIOSCIENCES, LLC a subsidiary
named as the applicant on its applications, in US
0 granted
2 published
EPYGENIX THERAPEUTICS, INC. a subsidiary
US, as the owner printed on each patent
0 granted
1 published
Names not counted (2)
Zynerba Pharmaceuticals Pty Ltd
Most of its patents print US; this name counts in AU. 13 granted and 41 published under it are not counted.
Zynerba Pharmaceuticals Pty Ltd
Most of its patents print US; this name counts in AU. 0 granted and 42 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,508,270Treatment of behavioral impairment in developmental and epileptic encephalopathyPharmaceuticalsHarmony Biosciences Management, Inc.
Feb 18, 202512,226,373Treatment of fragile X syndrome with cannabidiolPharmaceuticalsHarmony Biosciences Management, Inc.
Feb 4, 202512,213,951Treatment of autism with cannabidiolPharmaceuticalsHarmony Biosciences Management, Inc.
Jan 7, 202512,186,282Treatment of 22Q11.2 deletion syndrome with cannabidiolPharmaceuticalsHarmony Biosciences Management, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 6, 20252025/0339450TREATMENT OF SYNGAP1 ENCEPHALOPATHYPharmaceuticalsHarmony Biosciences Management, Inc.
Oct 2, 20252025/0302734SYNTHETIC TRANSDERMAL CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTSPharmaceuticalsHarmony Biosciences Management, Inc.
Sep 18, 20252025/0288539TREATMENT OF FRAGILE X SYNDROME AND AUTISM SPECTRUM DISORDER WITH CANNABIDIOLPharmaceuticalsHarmony Biosciences Management, Inc.
Aug 28, 20252025/0268843METHODS OF TREATMENT OF OSTEOARTHRITIS WITH TRANSDERMAL CANNABIDIOL GELPharmaceuticalsHarmony Biosciences Management, Inc.
Jun 26, 20252025/0205174TREATMENT OF 22Q11.2 DELETION SYNDROME WITH CANNABIDIOLPharmaceuticalsHarmony Biosciences Management, Inc.
Jun 19, 20252025/0195451TREATMENT OF SYNGAP1 ENCEPHALOPATHYPharmaceuticalsHarmony Biosciences Management, Inc.
Jun 5, 20252025/0177322TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOLPharmaceuticalsHarmony Biosciences Management, Inc.
May 1, 20252025/0134833TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOLPharmaceuticalsHarmony Biosciences Management, Inc.
May 1, 20252025/0134832TREATMENT OF AUTISM WITH CANNABIDIOLPharmaceuticalsHarmony Biosciences Management, Inc.
Apr 17, 20252025/0120951CLEMIZOLE FORMULATIONPharmaceuticalsEPYGENIX THERAPEUTICS, INC.
What it applied for, 2024 to 2025: Pharmaceuticals 11.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton HRMY · research, not advice